All eyes on oral MS drug Tecfidera as Biogen issues results, guidance
This article was originally published in Scrip
As Biogen Idec reported a 9% year-over-year increase in annual revenue to $5.5 billion in 2012, all eyes were focused on sales of the oral multiple sclerosis (MS) drug Tecfidera (formerly BG-12) as the company and its investors eagerly await a US FDA approval decision within the next two months.
You may also be interested in...
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.